Shares of EXACT Sciences Co. (NASDAQ:EXAS) have been given an average recommendation of “Hold” by the seventeen brokerages that are presently covering the stock, MarketBeat reports. Nine equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $50.97.

A number of brokerages recently weighed in on EXAS. BidaskClub lowered shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday. Benchmark reaffirmed a “buy” rating and issued a $60.00 target price (up from $50.00) on shares of EXACT Sciences in a research note on Tuesday, October 31st. Leerink Swann reaffirmed an “outperform” rating and issued a $50.00 target price (up from $45.00) on shares of EXACT Sciences in a research note on Thursday, September 21st. Bank of America upped their target price on shares of EXACT Sciences from $56.00 to $58.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Finally, Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a research report on Tuesday, September 26th.

Shares of EXACT Sciences (NASDAQ EXAS) traded up $0.34 during midday trading on Friday, reaching $51.56. 2,696,487 shares of the company were exchanged, compared to its average volume of 2,459,999. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98. EXACT Sciences has a 12-month low of $13.05 and a 12-month high of $63.60.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The company’s revenue for the quarter was up 158.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.36) EPS. sell-side analysts expect that EXACT Sciences will post -1.12 earnings per share for the current year.

In other news, insider Graham Peter Lidgard sold 81,025 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $3,821,139.00. Following the sale, the insider now directly owns 366,519 shares of the company’s stock, valued at approximately $17,285,036.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP D Scott Coward sold 29,115 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the sale, the senior vice president now directly owns 64,991 shares in the company, valued at $3,064,975.56. The disclosure for this sale can be found here. Insiders have sold a total of 595,396 shares of company stock worth $32,953,769 over the last three months. Insiders own 4.00% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Fortaleza Asset Management Inc. bought a new stake in shares of EXACT Sciences in the 2nd quarter valued at about $106,000. Oppenheimer Asset Management Inc. raised its holdings in shares of EXACT Sciences by 2,925.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock valued at $150,000 after purchasing an additional 3,072 shares during the period. SG Americas Securities LLC bought a new stake in shares of EXACT Sciences in the 3rd quarter valued at about $183,000. Krilogy Financial LLC raised its holdings in shares of EXACT Sciences by 1,460.0% in the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after purchasing an additional 3,650 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of EXACT Sciences by 17.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 600 shares during the period. 82.39% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “EXACT Sciences Co. (EXAS) Receives Consensus Rating of “Hold” from Analysts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/15/exact-sciences-co-exas-receives-consensus-rating-of-hold-from-analysts.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.